Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

46.18 +6.26 (+15.68%)
Streaming Delayed Price Updated: 11:46 AM EDT, Aug 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
UroGen Pharma to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Appoints David Lin as New Chief Commercial Officer
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
From UroGen Pharma Ltd.
Via Business Wire
News headline image
URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q1 2024 ↗
URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Earnings Outlook For UroGen Pharma ↗
 
Via Benzinga
News headline image
Recap: UroGen Pharma Q3 Earnings ↗
 
Via Benzinga
News headline image
Preview: UroGen Pharma's Earnings ↗
 
Via Benzinga
News headline image
UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Participate at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via Business Wire
News headline image
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
From UroGen Pharma Ltd.
Via Business Wire
News headline image
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
From UroGen Pharma Ltd.
Via Business Wire
News headline image
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. 
Via Benzinga
News headline image
URGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023 ↗
URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
From UroGen Pharma Ltd.
Via Business Wire
News headline image
Earnings Scheduled For March 14, 2024 ↗
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Participate at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma to Participate in the B. Riley Healthcare Conference
From UroGen Pharma Ltd.
Via Business Wire
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via Business Wire
News headline image
Two Months After Hamas Attacks, Gaza Conflict Intensifies As Ceasefire Efforts Falter ↗
Two months after Hamas attacks, US President Biden, UNSC & King of Jordan call for ceasefire. Israeli stocks rise, US envoy to UN against ceasefire. Investigations into civilian casualties & use of... 
Via Benzinga
News headline image
UroGen Pharma Reports Third Quarter 2023 Financial Results
From UroGen Pharma Ltd.
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.